Steven Goodman

Senior Director, AAV Process Development and Manufacturing Vertex Pharmaceuticals

Steve Goodman joined VCGT as Senior Director, AAV Process Development and Manufacturing. Prior to this, Steve was the head of drug product manufacturing at bluebird bio, where he oversaw production of cellular therapies across their portfolio of products and is accountable for the long-term technology strategy to expand access of these treatments to serve global patient requirements. Before joining bluebird in January 2018, Steve was at GSK where he held a number of roles across research, development, manufacturing and supply chain. As Director of Manufacturing and Strategy for GSK’s CGT unit, he was responsible for the external manufacturing of the entire value chain to support GSK’s cellular therapies, and for defining and executing the vector manufacturing strategy. Steve joined GSK in 2002 following a Ph.D. and post-doctoral fellowship in organic synthetic chemistry at Harvard University.